Von willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 1, 2010, Pages 71-81

  Zhou, Zhou ^a   Nguyen, Trung C ^a   Guchhait, Prasenjit ^a   Dong, Jing Fei ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

ADAMTS 13; Fluid shear stress; Thrombotic thrombocytopenic purpura; TTP; Von Willebrand factor

Indexed keywords

VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

CAUSAL ATTRIBUTION; DRUG ACTIVITY; DRUG INDICATION; ENZYME SUBSTRATE COMPLEX; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROTEIN INTERACTION; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ANIMALS; HUMANS; PROTEIN MULTIMERIZATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 77951073606     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1248726     Document Type: Review

References (165)

1. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924 24 21
2. Amorosi E L., Ultamann J E. Thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966 45 139-159
3. Moake J L., Rudy C K., Troll J H. et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982 307 (23) 1432-1435
4. Moake J L., Turner N A., Stathopoulos N A., Nolasco L H., Hellums J D. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986 78 (6) 1456-1461
5. Moake J L., Turner N A., Stathopoulos N A., Nolasco L, Hellums J D. Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988 71 (5) 1366-1374
6. Arya M, Anvari B, Romo G M. et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002 99 (11) 3971-3977
7. Furlan M, Robles R, Lmmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 87 (10) 4223-4234 (Pubitemid 26152266)
8. Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 87 (10) 4235-4244
9. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001 98 (6) 1662-1666
10. Levy G G., Nichols W C., Lian E C. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 413 (6855) 488-494 (Pubitemid 32938741)
11. Zheng X, Chung D, Takayama T K., Majerus E M., Sadler J E., Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001 276 (44) 41059-41063 (Pubitemid 37373259)
12. Furlan M, Robles R, Solenthaler M, Lmmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998 91 (8) 2839-2846 (Pubitemid 28227534)
13. Tsai H M., Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 (22) 1585-1594 (Pubitemid 28536133)
14. Scheiflinger F, Knbl P, Trattner B et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood 2003 102 (9) 3241-3243 (Pubitemid 37314762)
15. Weibel E R., Palade G E. New cytoplasmic components in arterial endothelia. J Cell Biol 1964 23 101-112
16. Bowie E J., Solberg L A. Jr, Fass D N. et al. Transplantation of normal bone marrow into a pig with severe von Willebrands disease. J Clin Invest 1986 78 (1) 26-30
17. Ginsburg D, Handin R I., Bonthron D T. et al. Human von Willebrand factor (VWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 1985 228 (4706) 1401-1406 (Pubitemid 15041316)
18. Wagner D D., Marder V J. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984 99 (6) 2123-2130
19. Wagner D D., Lawrence S O., Ohlsson-Wilhelm B M., Fay P J., Marder V J. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987 69 (1) 27-32
20. Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik J A., Pannekoek H. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J Cell Biol 1991 113 (1) 195-205 (Pubitemid 21909686)
21. Katsumi A, Tuley E A., Bod I, Sadler J E. Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor. J Biol Chem 2000 275 (33) 25585-25594
22. Purvis A R., Gross J, Dang L T. et al. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc Natl Acad Sci U S A 2007 104 (40) 15647-15652 (Pubitemid 350035354)
23. Wagner D D., Fay P J., Sporn L A., Sinha S, Lawrence S O., Marder V J. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells. Proc Natl Acad Sci U S A 1987 84 (7) 1955-1959
24. Verweij C L., Hart M, Pannekoek H. Expression of variant von Willebrand factor (VWF) cDNA in heterologous cells: requirement of the pro-polypeptide in VWF multimer formation. EMBO J 1987 6 (10) 2885-2890
25. Wise R J., Pittman D D., Handin R I., Kaufman R J., Orkin S H. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 1988 52 (2) 229-236 (Pubitemid 18043596)
26. Sporn L A., Marder V J., Wagner D D. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986 46 (2) 185-190
27. Mannucci P M. Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proc Natl Acad Sci U S A 1995 92 (7) 2428-2432
28. Huang R H., Wang Y, Roth R et al. Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci U S A 2008 105 (2) 482-487 (Pubitemid 351171734)
29. Berriman J A., Li S, Hewlett L J. et al. Structural organization of Weibel-Palade bodies revealed by cryo-EM of vitrified endothelial cells. Proc Natl Acad Sci U S A 2009 106 (41) 17407-17412
30. Michaux G, Abbitt K B., Collinson L M., Haberichter S L., Norman K E., Cutler D F. The physiological function of von Willebrands factor depends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 2006 10 (2) 223-232 (Pubitemid 43174955)
31. Schorer A E., Moldow C F., Rick M E. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987 67 (2) 193-197 (Pubitemid 18029653)
32. Paleolog E M., Crossman D C., McVey J H., Pearson J D. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990 75 (3) 688-695
33. Padilla A, Moake J L., Bernardo A et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004 103 (6) 2150-2156 (Pubitemid 38326232)
34. Huang J, Roth R, Heuser J E., Sadler J E. Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood 2009 113 (7) 1589-1597
35. Chauhan A K., Goerge T, Schneider S W., Wagner D D. Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 2007 5 (3) 583-589 (Pubitemid 46680693)
36. Dong J F., Moake J L., Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002 100 (12) 4033-4039 (Pubitemid 35396870)
37. Bernardo A, Ball C, Nolasco L, Choi H, Moake J L., Dong J F. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 2005 3 (3) 562-570 (Pubitemid 41632882)
38. Groot E, Fijnheer R, Sebastian S A., de Groot P G., Lenting P J. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost 2009 7 (6) 962-969
39. Martin C, Morales L D., Cruz M A. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 2007 5 (7) 1363-1370
40. Siedlecki C A., Lestini B J., Kottke-Marchant K K., Eppell S J., Wilson D L., Marchant R E. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996 88 (8) 2939-2950
41. Shankaran H, Alexandridis P, Neelamegham S. Aspects of hydrodynamic shear regulating shear-induced platelet activation and self-association of von Willebrand factor in suspension. Blood 2003 101 (7) 2637-2645
42. Schneider S W., Nuschele S, Wixforth A et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 2007 104 (19) 7899-7903
43. Choi H, Aboulfatova K, Pownall H J., Cook R, Dong J F. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem 2007 282 (49) 35604-35611
44. Li Y, Choi H, Zhou Z et al. Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions. J Thromb Haemost 2008 6 (7) 1135-1143
45. Xie L, Chesterman C N., Hogg P J. Reduction of von Willebrand factor by endothelial cells. Thromb Haemost 2000 84 (3) 506-513
46. Xie L, Chesterman C N., Hogg P J. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2001 193 (12) 1341-1349
47. Pimanda J E., Annis D S., Raftery M, Mosher D F., Chesterman C N., Hogg P J. The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood 2002 100 (8) 2832-2838
48. Chen J, Fu X, Wang Y et al. Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood 2009 October 7 (Epub ahead of print)
49. Porter S, Clark I M., Kevorkian L, Edwards D R. The ADAMTS metalloproteinases. Biochem J 2005 386 (Pt 1) 15-27
50. Anderson P J., Kokame K, Sadler J E. Zinc and calcium ions cooperatively modulate ADAMTS13 activity. J Biol Chem 2006 281 (2) 850-857
51. Gardner M D., Chion C K., de Groot R, Shah A, Crawley J T., Lane D A. A functional calcium-binding site in the metalloprotease domain of ADAMTS13. Blood 2009 113 (5) 1149-1157
52. Mannucci P M., Canciani M T., Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001 98 (9) 2730-2735
53. Tsai H M., Sarode R, Downes K A. Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood. Thromb Res 2002 108 (23) 121-125
54. Uemura M, Tatsumi K, Matsumoto M et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005 106 (3) 922-924
55. Zhou W, Inada M, Lee T P. et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005 85 (6) 780-788
56. Suzuki M, Murata M, Matsubara Y et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004 313 (1) 212-216
57. Liu L, Choi H, Bernardo A et al. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005 3 (11) 2536-2544
58. Turner N, Nolasco L, Tao Z, Dong J F., Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006 4 (6) 1396-1404
59. Davis A K., Makar R S., Stowell C P., Kuter D J., Dzik W H. ADAMTS13 binds to CD36: a potential mechanism for platelet and endothelial localization of ADAMTS13. Transfusion 2009 49 (2) 206-213
60. Vomund A N., Majerus E M. ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor. J Biol Chem 2009 284 (45) 30925-30932
61. Turner N A., Nolasco L, Ruggeri Z M., Moake J L. Endothelial cell ADAMTS-13 and VWF: production, release and VWF string cleavage. Blood 2009 114 (24) 5102-5111
62. Shang D, Zheng X W., Niiya M, Zheng X L. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 2006 108 (7) 2207-2215
63. Zhou Z, Jing H, Tao Z et al. Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13. Thromb Res 2009 124 (3) 323-327
64. Ricketts L M., Dlugosz M, Luther K B., Haltiwanger R S., Majerus E M. O-fucosylation is required for ADAMTS13 secretion. J Biol Chem 2007 282 (23) 17014-17023
65. Zhou W, Tsai H M. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood 2009 113 (4) 929-935
66. Cao W J., Niiya M, Zheng X W., Shang D Z., Zheng X L. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008 6 (7) 1233-1235
67. Nguyen T C., Liu A, Liu L et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haemtologica 2007 92 121-124
68. Kremer Hovinga J A., Zeerleder S, Kessler P et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007 5 (11) 2284-2290
69. Zheng X, Nishio K, Majerus E M., Sadler J E. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem 2003 278 (32) 30136-30141
70. Majerus E M., Anderson P J., Sadler J E. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem 2005 280 (23) 21773-21778
71. Zhou W, Dong L, Ginsburg D, Bouhassira E E., Tsai H M. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem 2005 280 (48) 39934-39941
72. Feys H B., Anderson P J., Vanhoorelbeke K, Majerus E M., Sadler J E. Multi-step binding of ADAMTS13 to VWF. J Thromb Haemost 2009 7 (12) 2088-2095
73. Soejima K, Matsumoto M, Kokame K et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood 2003 102 (9) 3232-3237
74. Ai J, Smith P, Wang S, Zhang P, Zheng X L. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem 2005 280 (33) 29428-29434
75. Gao W, Anderson P J., Majerus E M., Tuley E A., Sadler J E. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A 2006 103 (50) 19099-19104
76. de Groot R, Bardhan A, Ramroop N, Lane D A., Crawley J T. Essential role of the disintegrin-like domain in ADAMTS13 function. Blood 2009 113 (22) 5609-5616
77. Zhang P, Pan W, Rux A H., Sachais B S., Zheng X L. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 2007 110 (6) 1887-1894
78. Tao Z, Peng Y, Nolasco L et al. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 2005 106 (13) 4139-4145
79. Tao Z, Wang Y, Choi H et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 2005 106 (1) 141-143
80. Akiyama M, Takeda S, Kokame K, Takagi J, Miyata T. Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor. Proc Natl Acad Sci U S A 2009 106 (46) 19274-19279
81. Dong J F., Moake J L., Bernardo A et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003 278 (32) 29633-29639
82. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004 103 (2) 607-612
83. Wu J J., Fujikawa K, McMullen B A., Chung D W. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A 2006 103 (49) 18470-18474
84. Zanardelli S, Crawley J T., Chion C K., Lam J K., Preston R J., Lane D A. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem 2006 281 (3) 1555-1563 (Pubitemid 43752470)
85. Jenkins P V., Pasi K J., Perkins S J. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrands disease. Blood 1998 91 (6) 2032-2044
86. Tsai H M., Sussman I I., Nagel R L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994 83 (8) 2171-2179 (Pubitemid 24112728)
87. Tsai H M. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost 2003 29 (5) 479-488
88. Baldauf C, Schneppenheim R, Stacklies W, et al. Shear-induced unfolding activates von Willebrand factor A2 domain for proteolysis. J Thromb Haemost 2009 7 (12) 2096-2105
89. Zhang X, Halvorsen K, Zhang C Z., Wong W P., Springer T A. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 2009 324 (5932) 1330-1334
90. Wu T, Lin J, Cruz M A., Dong J F., Zhu C. Force-induced cleavage of single VWF A1A2A3-tridomains by ADAMTS-13. Blood 2010 115 (2) 370-378
91. Nishio K, Anderson P J., Zheng X L., Sadler J E. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A 2004 101 (29) 10578-10583 (Pubitemid 38955784)
92. Shim K, Anderson P J., Tuley E A., Wiswall E, Sadler J E. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008 111 (2) 651-657
93. Cao W, Krishnaswamy S, Camire R M., Lenting P J., Zheng X L. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc Natl Acad Sci U S A 2008 105 (21) 7416-7421 (Pubitemid 351830032)
94. Zanardelli S, Chion A C., Groot E et al. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood 2009 114 (13) 2819-2828
95. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007 33 (8) 787-797 (Pubitemid 351158447)
96. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lmmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997 89 (9) 3097-3103 (Pubitemid 27229791)
97. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 (22) 1578-1584 (Pubitemid 28536132)
98. Furlan M, Robles R, Morselli B, Sandoz P, Lmmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999 81 (1) 8-13 (Pubitemid 29041640)
99. Kokame K, Matsumoto M, Soejima K et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002 99 (18) 11902-11907 (Pubitemid 34994496)
100. Antoine G, Zimmermann K, Plaimauer B et al. ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 2003 120 (5) 821-824 (Pubitemid 36315105)
101. Assink K, Schiphorst R, Allford S et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003 63 (6) 1995-1999 (Pubitemid 36605810)
102. Savasan S, Lee S K., Ginsburg D, Tsai H M. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003 101 (11) 4449-4451 (Pubitemid 36857812)
103. Schneppenheim R, Budde U, Oyen F et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003 101 (5) 1845-1850 (Pubitemid 36237583)
104. Matsumoto M, Kokame K, Soejima K et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 2004 103 (4) 1305-1310 (Pubitemid 38168641)
105. Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 2004 66 (3) 955-958 (Pubitemid 39120997)
106. Uchida T, Wada H, Mizutani M et al, Research Project on Genetics of Thrombosis. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 2004 104 (7) 2081-2083
107. Pimanda J E., Maekawa A, Wind T, Paxton J, Chesterman C N., Hogg P J. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13. Blood 2004 103 (2) 627-629
108. Furlan M, Lmmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001 14 (2) 437-454
109. Tao Z, Anthony K, Peng Y et al. Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 2006 4 (9) 1931-1935
110. Motto D G., Chauhan A K., Zhu G et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005 115 (10) 2752-2761
111. Karmali M A., Steele B T., Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983 1 (8325) 619-620
112. Nolasco L H., Turner N A., Bernardo A et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005 106 (13) 4199-4209
113. Chauhan A K., Walsh M T., Zhu G, Ginsburg D, Wagner D D., Motto D G. The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. Blood 2008 111 (7) 3452-3457
114. Studt J D., Hovinga J A., Antoine G et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005 105 (2) 542-544
115. Donadelli R, Banterla F, Galbusera M et al, International Registry of Recurrent and Familial HUS/TTP. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006 96 (4) 454-464
116. Kokame K, Miyata T. Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 2004 41 (1) 34-40
117. Plaimauer B, Fuhrmann J, Mohr G et al. Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 2006 107 (1) 118-125
118. Bongers T N., De Maat M P., Dippel D W., Uitterlinden A G., Leebeek F W. Absence of Pro475Ser polymorphism in ADAMTS-13 in Caucasians. J Thromb Haemost 2005 3 (4) 805
119. Ruan C, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders. Thromb Haemost 2004 91 (6) 1257-1258
120. Terrell D R., Williams L A., Vesely S K., Lmmle B, Hovinga J A., George J N. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005 3 (7) 1432-1436
121. Egerman R S., Witlin A G., Friedman S A., Sibai B M. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: review of 11 cases. Am J Obstet Gynecol 1996 175 (4 Pt 1) 950-956
122. McCrae K R., Cines D B. Thrombotic microangiopathy during pregnancy. Semin Hematol 1997 34 (2) 148-158
123. Gerth J, Schleussner E, Kentouche K, Busch M, Seifert M, Wolf G. Pregnancy-associated thrombotic thrombocytopenic purpura. Thromb Haemost 2009 101 (2) 248-251
124. Rieger M, Mannucci P M., Kremer Hovinga J A. et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005 106 (4) 1262-1267
125. Austin S K., Starke R D., Lawrie A S., Cohen H, Machin S J., Mackie I J. The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. Br J Haematol 2008 141 (4) 536-544
126. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 2009 102 (2) 371-378
127. Shimizu M, Nomura S, Ishii K et al. The significance of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura complicated autoimmune hepatitis. Thromb Haemost 2009 101 (3) 599-600
128. Kiki I, Gundogdu M, Albayrak B, Bilgi Y. Thrombotic thrombocytopenic purpura associated with Brucella infection. Am J Med Sci 2008 335 (3) 230-232
129. Rossi F C., Angerami R N., de Paula E V. et al. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection. Transfusion 2009 September 24 (Epub ahead of print)
130. Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005 42 (3) 420-421
131. Uemura M, Fujimura Y, Matsumoto M et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008 99 (6) 1019-1029
132. Bennett C L., Connors J M., Carwile J M. et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000 342 (24) 1773-1777
133. Bennett C L., Kim B, Zakarija A et al, SERF-TTP Research Group. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007 50 (12) 1138-1143
134. Zakarija A, Kwaan H C., Moake J L. et al. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (19892008). Kidney Int Suppl 2009 112 S20-S24
135. Vesely S K., George J N., Lmmle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003 102 (1) 60-68
136. Shelat S G., Smith P, Ai J, Zheng X L. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006 4 (8) 1707-1717
137. Shelat S G., Ai J, Zheng X L. Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost 2005 31 (6) 659-672
138. Ferrari S, Mudde G C., Rieger M, Veyradier A, Kremer Hovinga J A., Scheiflinger F. IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2009 7 (10) 1703-1710
139. Klaus C, Plaimauer B, Studt J D. et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood 2004 103 (12) 4514-4519
140. Luken B M., Kaijen P H., Turenhout E A. et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2006 4 (11) 2355-2364
141. Luken B M., Turenhout E A., Kaijen P H. et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 2006 96 (3) 295-301
142. Moake J L., Byrnes J J. Thrombotic microangiopathies associated with drugs and bone marrow transplantation. Hematol Oncol Clin North Am 1996 10 (2) 485-497
143. Elliott M A., Nichols W L. Jr, Plumhoff E A. et al. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003 78 (4) 421-430
144. Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrands factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999 59 (9) 2244-2250
145. Mannucci P M., Karimi M, Mosalaei A, Canciani M T., Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 2003 88 (4) 454-458
146. Medina P J., Sipols J M., George J N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001 8 (5) 286-293
147. Sugimoto T, Saigo K, Shin T et al. Von Willebrand factor-cleaving protease activity remains at the intermediate level in thrombotic thrombocytopenic purpura. Acta Haematol 2005 113 (3) 198-203
148. Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005 31 (6) 681-690
149. Bernardo A, Ball C, Nolasco L, Moake J F., Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004 104 (1) 100-106
150. Crawley J T., Lane D A., Woodward M, Rumley A, Lowe G D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008 6 (4) 583-588
151. Fuchigami S, Kaikita K, Soejima K et al. Changes in plasma von Willebrand factor-cleaving protease (ADAMTS13) levels in patients with unstable angina. Thromb Res 2008 122 (5) 618-623
152. Bongers T N., de Bruijne E L., Dippel D W. et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis 2009 207 (1) 250-254
153. Gombos T, Mak V, Cervenak L et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009 102 (3) 573-580
154. Bongers T N., de Maat M P., van Goor M L. et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006 37 (11) 2672-2677
155. Vergouwen M D., Bakhtiari K, van Geloven N, Vermeulen M, Roos Y B., Meijers J C. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009 29 (10) 1734-1741
156. Matsuyama T, Uemura M, Ishikawa M et al. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2007 31 (1, suppl) S27-S35
157. Uemura M, Fujimura Y, Matsuyama T et al. Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Curr Drug Abuse Rev 2008 1 (2) 188-196
158. Morioka C, Uemura M, Matsuyama T et al. Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis. Scand J Gastroenterol 2008 43 (11) 1387-1396
159. de Mast Q, Groot E, Lenting P J. et al. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis 2007 196 (4) 622-628
160. de Mast Q, Groot E, Asih P B. et al, de MQ. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg 2009 80 (3) 492-498
161. Larkin D, de Laat B, Jenkins P V. et al. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLoS Pathog 2009 5 (3) e1000349
162. Nguyen T C., Han Y Y., Kiss J E. et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia- associated multiple organ failure. Crit Care Med 2008 36 (10) 2878-2887
163. Zhou Z, Han H, Cruz M A., Lpez J A., Dong J F., Guchhait P. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 2009 101 (6) 1070-1077
164. Chauhan A K., Motto D G., Lamb C B. et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006 203 (3) 767-776
165. Zhao B Q., Chauhan A K., Canault M et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 2009 114 (15) 3329-3334